How to buy Regeneron (REGN) stock from India

Yes, an Indian resident can buy Regeneron — legally, in US dollars, under the RBI's Liberalised Remittance Scheme (LRS). The buying is the easy 10%; the 90% that decides your outcome is tax, estate-tax exposure, and position sizing. REGN pays no dividend, so US withholding and Form 67 are essentially a non-issue. The short version is below.

The 30-second version

• Legal and simple. Buy REGN via any India-facing platform (Vested, INDmoney) or a global broker (Interactive Brokers, Rovia). Whole share or fractional rupee amount — fractional matters because REGN trades in the mid-three-figure dollar range.
• Pure capital-gains play. REGN has never paid a dividend; capital return runs through buybacks, so US withholding and Form 67 are essentially irrelevant — unusual for a biotech this size.
• India tax: hold more than 24 months and pay 12.5% LTCG (no indexation); sell sooner and pay your slab rate. This is Section 112, not the friendlier 112A that Indian shares get.
• The trap most miss: directly-held REGN is a US-situs asset — above $60,000, your estate faces up to 40% US estate tax, with no India-US treaty relief.
• If your thesis is "US biotech," IBB or XBI hold REGN as a top weight, and QQQ, VOO, and VTI carry it inside broader baskets — same exposure, no single-stock risk.

Quick facts

Can an Indian resident buy it?	Yes — fully legal under the LRS
Ticker / exchange	REGN / Nasdaq
How	India-facing platform (Vested, INDmoney) or global broker (IBKR, Rovia)
Minimum	A fraction of one share (fractional matters at a mid-three-figure share price)
Dividend	None — REGN has never paid one; capital return runs through buybacks
India tax on gains	12.5% LTCG after 24 months; else your slab (Section 112)
Estate-tax risk	US-situs above $60k means up to 40%, no treaty relief
Annual compliance	Schedule FA disclosure, every year you hold

How to buy it — 3 steps

1. Open an account and finish KYC. Pick an India-facing platform (Vested, INDmoney) for a simple India-funded experience, or a global broker (Interactive Brokers, Rovia) for wider access. File your W-8BEN during onboarding — good practice even with no current dividend, because it covers any future distribution. New to this? Start with how to invest in US stocks from India.
2. Fund it via the LRS. Remit from your Indian bank (cap: $250,000 per financial year). 20% TCS applies above ten lakh rupees in a year — a creditable prepayment, not a cost. See LRS explained and the LRS and TCS calculator.
3. Place the order. REGN trades in the mid-three-figure dollar range — at USD/INR 87, a share near $550 is roughly 47,850 rupees. Fractional ordering lets you size to an exact rupee figure rather than rounding up to a whole share.

The tax that actually matters

Regeneron pays no dividend, so the 25% US withholding and annual Form 67 dance — a recurring headache with names like Microsoft or Apple — does not apply here. Your entire tax exposure is on capital gains when you sell, under Section 112 (foreign shares don't get the Section 112A treatment Indian-listed equity enjoys):

Holding period	Treatment	Rate
24 months or less	Short-term	Your slab rate (up to roughly 30% plus surcharge)
More than 24 months	Long-term	12.5%, no indexation

Worked example. Buy 2 shares at $480 when USD/INR is 86 → cost 82,560 rupees. Sell 28 months later at $620 when USD/INR is 88 → proceeds 1,09,120 rupees. Taxable gain 26,560 rupees; LTCG at 12.5% = 3,320 rupees. The gain is computed in rupees, so a weaker rupee at sale amplifies your reported gain — and at REGN's price, fractional sizing matters. Model your own with the US capital-gains calculator; full rules in how US stocks are taxed in India. For Form 67 context (relevant if you also hold dividend-paying US names), see dividend withholding and Form 67.

The $60,000 estate-tax trap

Directly-held REGN is a US-situs asset. If the holder dies with more than $60,000 of US-situs assets, the estate faces US estate tax up to 40% — and the India-US treaty does not cover estate tax, so there's no credit or relief. At REGN's price the threshold arrives fast: roughly 100-130 shares puts you over the line on this name alone. The fix (holding through pooled or fund structures rather than direct shares) has to be a deliberate choice made before the position gets large. Full detail: the $60,000 estate-tax trap.

Buy the stock, or get Regeneron through an ETF?

If you want…	Best route
A concentrated bet that REGN beats its biotech peers	REGN directly
"US biotech innovation will keep winning" exposure	IBB or XBI — REGN is a top weight, plus dozens of other biotechs
Broad US large-cap exposure including REGN	QQQ, VOO, or VTI — REGN sits inside the Nasdaq and S&P baskets
Zero dividend-tax paperwork on the position	REGN works either way — it pays nothing
The least single-stock risk	A broad ETF

Regeneron is a meaningful weight in IBB (Nasdaq Biotech ETF) and XBI (equal-weighted biotech), and sits inside QQQ, VOO, and VTI as part of the broader large-cap basket. An index or sector fund gives you REGN exposure proportional to its size — plus dozens or hundreds of other names, one Schedule FA entry, and cleaner estate-tax treatment via pooled vehicles. Compare the routes in direct stocks vs US ETFs and best US ETFs for Indian investors; the broader case is in US ETFs for Indians.

The business in one screen

What it is: Regeneron runs on two megablockbuster engines — Eylea and Eylea HD in ophthalmology (wet AMD, diabetic eye disease), and Dupixent in immunology (atopic dermatitis, asthma, and a widening list of indications) co-developed with Sanofi, who takes roughly half the profits. Behind that sits a pipeline: Libtayo in immuno-oncology, a factor XI anticoagulant program, and gene-editing assets — most catalysts 2027 and later.

Bull case	Bear case
Dupixent expanding into COPD, eosinophilic esophagitis, prurigo nodularis	Legacy Eylea 2mg facing accelerating biosimilar competition
Eylea HD (8mg) conversion offsetting legacy biosimilar erosion	Dupixent at over 13 billion dollars is mature with deceleration risk
Deep pipeline with Sanofi partnership de-risking funding	Sanofi takes roughly 50% of Dupixent profits, structurally capping upside
Strong free cash flow and disciplined buyback program	Pipeline catalysts largely back-loaded to 2027 and beyond
	Valuation full given the near-term franchise compression

Exact valuation is in the live widget above — a high-quality biotech in transition, not a momentum name.

Our take

Verdict: HOLD — two megablockbusters and a clean tax profile, but no near-term acceleration catalyst worth chasing.

• Two real franchises, both with overhangs. Eylea HD is converting well, but legacy 2mg biosimilars are compressing the franchise faster than HD is replacing volume. Dupixent is great — over 13 billion dollars in sales and still adding indications — but Sanofi takes half the profits and growth is decelerating off a high base.
• Pipeline is back-loaded. Libtayo, the factor XI anticoag program, and gene-editing assets are interesting, but the meaningful readouts cluster in 2027 and beyond. A full multiple today pays for a transition, not an acceleration.
• Best as a patient-quality compounder, not a fresh BUY. Clean balance sheet, strong free cash flow, no dividend friction, Section 112 long-term rate of 12.5% — fine to hold if you already own it. We wouldn't add aggressively without a clearer catalyst.

Compliance note. Vested.blog is not a SEBI-registered Research Analyst. The above is an editorial opinion for educational illustration only — not investment advice and not a regulated stock recommendation. Vested.blog is published by Rovia; the publisher and its affiliates may hold positions in stocks discussed. Make your own decisions or consult a SEBI-registered advisor.

Risks to size for

• Eylea biosimilar erosion: legacy 2mg faces accelerating biosimilar competition in the US and Europe; if Eylea HD conversion stalls, total ophthalmology revenue compresses faster than consensus expects.
• Dupixent maturity and Sanofi economics: Dupixent is the single largest profit driver and is decelerating off a large base, while Sanofi takes roughly half the economics — a single disappointment here hits hard.
• Pipeline binary readouts: biotech catalysts are binary; a missed phase-3 readout in factor XI or oncology can move REGN double digits in a session.
• Currency: your return is in USD but you spend rupees — see the rupee-dollar effect.

Two things people forget

• Schedule FA: disclose REGN in Schedule FA of your ITR every year you hold it — even if bought and sold within the year, even at a loss. Non-disclosure carries Black Money Act penalties. No dividend means you skip Form 67 — but Schedule FA is non-negotiable. Use the Schedule FA helper.
• Position size: a single biotech, however high-quality, is not an index — binary pipeline risk and biosimilar competition can re-rate the name in a single quarter. Size REGN as a high-conviction satellite, not a substitute for a broad ETF.

Bottom line

Buying REGN from India is easy and legal. What needs thought isn't the buying — it's that REGN is a Section-112 capital-gains play (12.5% after 24 months), a US-situs asset with a $60k estate-tax trap, and a single biotech needing disciplined sizing through the legacy Eylea biosimilar transition. The upside versus other biotechs: no dividend means no recurring 25% withholding and no Form 67 work. If your real thesis is "US biotech innovation," IBB or XBI gives broader exposure without the single-name concentration. For accounts and options, start at the US investing hub.

---

This article is general information, not personalised investment, tax, or legal advice. Rules, rates, and thresholds described here are as of 2026 and can change; verify the current position and consult a qualified advisor before acting.